Person: ERTÜRK, ELİF
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ERTÜRK
First Name
ELİF
Name
10 results
Search Results
Now showing 1 - 10 of 10
Publication Association between resistance to cinacalcet and parathyroid gland hyperplasia in kidney transplant recipients with persistent hypercalcemia(Avicenna Organ Transplant Center, 2020-01-01) ORUÇ, AYŞEGÜL; Ersoy, Alparslan; ERSOY, ALPARSLAN; Yıldız, Abdülmecid; Gül, Özen Öz; ÖZ GÜL, ÖZEN; Kocaeli, Ayşen Akkurt; Erturk, E.; ERTÜRK, ELİF; Ersoy, C.; ERSOY, CANAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji Anabilim Dalı.; 0000-0002-0342-9692; JQI-3400-2023; AAI-1005-2021; JFB-3910-2023; AAH-4002-2021; KFR-7347-2024Background: Persistent hypercalcemia and hyperparathyroidism after successful kidney transplantation can be detrimental in some recipients and should be ameliorated.Objective: To point out the concerns regarding resistance to cinacalcet in kidney transplant recipients with persistent hypercalcemia.Methods: 14 renal transplant recipients who received cinacalcet treatment because of persistent hypercalcemia were included in the study. Serum creatinine, estimated glomerular filtration rate (eGFR), calcium, phosphorus, and intact parathyroid hormone (PTH) levels at the baseline and throughout the treatment, and ultrasonography and parathyroid scintigraphy findings were recorded.Results: Cinacalcet treatment was initiated after a mean +/- SD of 20.7 +/- 19.7 months of transplantation and maintained for 16.9 +/- 7.9 months. Serum calcium levels were significantly decreased with the cinacalcet treatment. There were no significant changes in serum creatinine, eGFR, phosphorus, and PTH levels. In all participants, serum calcium levels were increased from 9.8 +/- 0.6 to 11.1 +/- 0.6 mg/dL (p<0.001) within 1 month of cessation of cinacalcet. 7 recipients with adenoma-like hyperplastic glands underwent parathyroidectomy (PTx) due to failure with cinacalcet.Conclusion: Cinacalcet may be an appropriate treatment for a group of recipients with hypercalcemia without adenoma-like hyperplastic glands or who had a contraindication for surgery. Recipients with enlarged parathyroid gland may resist to cinacalcet-induced decrease in serum PTH, although the concomitant hypercalcemia may be corrected.Publication Anticancer potential of albumin bound wnt/β-catenin pathway inhibitor niclosamide in breast cancer cells(Wiley-v C H Verlag Gmbh, 2021-08-06) Ari, Ferda; Erkisa, Merve; Pekel, Gonca; Buyukkoroglu, Gulay; Ulukaya, Engin; Erturk, Elif; ERTÜRK, ELİF; Arı, Ferda; Erkısa, Merve; Bursa Uludağ Üniversitesi/Fen Edebiyat Fakültesi/Biyoloji Bölümü.; Bursa Uludağ Üniversitesi/Sağlık Hizmetleri Meslek Yüksekokulu.; 0000-0002-6729-7908; 0000-0002-3127-742X; 0000-0002-5089-6007; 0000-0003-4875-5472; K-5792-2018; N-6551-2019; JQI-3400-2023; AAM-1001-2020; IWM-5784-2023Albumin-based nanoparticle transport systems (nab-technology) are a new strategy in cancer treatment and we aimed to increase the effectiveness of Niclosamide using this technology. Niclosamide was bound with bovine serum albumin (BSA) by desolvation to yield nanoparticle albumin-bound Niclosamide (nab-Niclo). Nab-Niclo anticancer activity was assessed by proliferation, apoptosis and DNA damage analyses on breast cancer cells. The results implied that nab-Niclo was a more potent agent in the inhibition of cell viability than free Niclosamide and albumin. Flow cytometry analysis show that nab-Niclo triggered apoptosis by caspase and mitochondriadependent pathways in cells and nab-Niclo enhances apoptosis by induce DNA damage in cells. Overall results of this study showed that the nanoparticle form of Niclosamide is effective for breast cancer treatment, presenting a new treatment strategy that can be safe and effective for breast cancer patients.Publication Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells(Tübitak Bilimsel ve Teknolojik Araştırma Kurumu, 2021-01-01) Ertürk, Elif; Arı, Ferda; Akgün, Oguzhan; Ulukaya, Engin; Küçükali, Cem İsmail; Zeybek, Ümit; ERTÜRK, ELİF; ARI, FERDA; Akgün, Oguzhan; 0000-0002-6729-7908; 0000-0002-8410-1786; 0000-0003-4875-5472; 0000-0001-9851-8577; A-5608-2019; K-5792-2018; JQI-3400-2023Understanding of the functions of microRNAs in breast cancer and breast cancer stem cells have been a hope for the development of new molecular targeted therapies. Here, it is aimed to investigate the differences in the expression levels of let-7a, miR-10b, miR-21, miR-125b, miR-145, miR-155, miR-200c, miR-221, miR-222 and miR-335, which associated with gene and proteins in MCF-7 (parental) and MCF-7s (Mammosphere/stem cell-enriched population/CD44+/CD24-cells) cells treated with paclitaxel. MCF7-s were obtained from parental MCF-7 cells. Cytotoxic activity of paclitaxel was determined by ATP assay. Total RNA isolation and cDNA conversion were performed from the samples. Changes in expression levels of miRNAs were examined by RT-qPCR. Identified target genes and proteins of miRNAs were analyzed with RT-qPCR and western blot analysis, respectively. miR-125b was significantly expressed (2.0946-fold; p = 0.021) in MCF-7s cells compared to control after treatment with paclitaxel. Downregulation of SMO, STAT3, NANOG, OCT4, SOX2, ERBB2 and ERBB3 and upregulation of TP53 genes were significant after 48 h treatment in MCF-7s cells. Protein expressions of SOX2, OCT4, SMAD4, SOX2 and OCT4 also decreased. Paclitaxel induces miR-125b expression in MCF-7s cells. Upregulation of miR-125b may be used as a biomarker for the prediction of response to paclitaxel treatment in breast cancer.Publication Retrospective analysis of vitamin D status on inflammatory markers and course of the disease in patients with COVID-19 infection(Springer, 2021-04-05) Ünsal, Yasemin Aydoğan; Gül, Özen Öz; Cander, Soner; Ersoy, Canan; Aydemir, Ensar; Ateş, Coşkun; Uzun, Ziya ; Armağan, Ersin; Ünsal, Oktay; Ertürk, Elif; AYDOĞAN ÜNSAL, YASEMİN; ÖZ GÜL, ÖZEN; CANDER, SONER; ERSOY, CANAN; AYDEMİR, ENSAR; ATEŞ, COŞKUN; ERTÜRK, ELİF; Armağan, Ersin; Uzun, Ziya; Bursa Uludağ Üniversitesi/Tıp Fakültesi; 0000-0002-1566-3099; 0000-0002-1332-4165; 0000-0001-6303-7896; 0000-0001-8519-784X; 0000-0003-4565-9848; 0000-0003-1363-2966; HSE-4469-2023; GBT-4320-2022; CJH-1319-2022; AAH-8861-2021; AAB-6671-2022; CDO-0747-2022; GQW-5454-2022; CBW-8706-2022; JQI-3400-2023Purpose The aim of the study was to investigate the association between serum 25-hydroxyvitamin D status within the last 6 months prior to COVID-19 infection and parameters of immune function and clinical outcomes. Methods Fifty-six patients, who were admitted to the emergency clinic and diagnosed with COVID-19 infection, were included in the study. Data on clinical characteristics, inflammatory parameters and vitamin D status were recorded for each patient. All the participants had data on 25-hydroxyvitamin D status within the last 6 months prior to COVID-19 infection. Results The patients were stratified as those with vitamin D status less than 20 ng/mL and higher than 20 ng/mL. A group with vitamin D status less than 20 ng/mL had lower lymphocyte counts and lower haemoglobin levels that was statistically significant (respectively; p = 0.021, p = 0.035). Higher C-reactive protein (CRP) levels were seen in the vitamin D-deficient group (p = 0.013). It was observed that vitamin D status of the patients who required oxygen therapy were lower than those who did not require oxygen therapy, not statistically significant (p = 0.05). Patients who did not use vitamin D supplementation within 6 months prior to COVID-19 infection had more likely to be diagnosed with pneumonia (p = 0.004). Conclusion Cases with lower vitamin D status had increased inflammatory markers and worse clinical outcomes than patients with higher vitamin D status. This study suggests that vitamin D status can be used as a prognostic factor in COVID-19 patients, and vitamin D supplementation can be recommended to improve the clinical outcomes in COVID-19 infection.Publication In vitro evaluations of antioxidant, antimicrobial and anticancer potential of phytolacca americana l. (pokeweed) seed extract(Trakya Univ Balkan Yerlesesi Enstituler Binasi, 2022-10-01) Çetinkaya, Aynur Aybey; DEMİRKAN, ELİF; YILDIZ, GAMZE; ERTÜRK, ELİF; SEVGİ, TUBA; Bursa Uludağ Üniversitesi/Fen Edebiyat Fakültesi/Biyoloji Bölümü.; Bursa Uludağ Üniversitesi/Sağlık Uygulama ve Araştırma Merkezi.; 0000-0002-5292-9482; 0000-0003-2743-9745; AAG-7112-2021; JQI-3400-2023In this study, different parts of Phytolacca americana L. (Pokeweed) fruit from Turkiye were investigated for their antioxidant, antibacterial, antibiofilm and anticancer potentials. The radical scavenging activities, reducing power and total phenolic content were determined to appraise of the antioxidant potentials. The antibacterial and antibiofilm activities of the extracts against Enterococcus faecalis, Yersinia enterocolitica, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Salmonella typhimurium were evaluated by using agar-well diffusion, minimum inhibitory concentration (MIC) and biofilm inhibitory concentration (BIC) assays. In addition of latening the onset of apoptosis depending on dose, the potential of the anti-proliferative effects was investigated on MDA-MB-231 and MCF-7 cells. The highest free radical scavenging activity and phenolic content were found in the seed extract. Seed extract showed the highest inhibition zones and significant antibacterial activity at 2.5-5 mg/mL MIC concentrations against tested bacterial strains. More significantly, seed extract was found effective on inhibition of early phase biofilm formation at 2.5-10 mg/mL. BIC concentrations against tested bacterial strains. Next, the main mechanisms of cell death of the seed extract in MDA-MB-231 and MCF-7 cells were investigated. Accordingly, when apoptosis was evaluated morphologically, late apoptosis was observed in cells that showed both Hoechst 33342 and Propidium Iodide (PI) positivity in a dose-dependent manner. This study showed that P. americana seed extract can contribute to alternative medicine studies and have potential power in pharmaceutical industry.Publication Mitochondrial mirnas (mitomirs): Their potential roles in breast and other cancers(Elsevier Sci Ltd, 2022-09-01) Ertürk, Elif; ARI, FERDA; ERTÜRK, ELİF; Onur, Ömer Enes; Akgün, Oğuzhan; Arı, Ferda; Tuna, Gonca; Yıldız, Yaren; Bursa Uludağ Üniversitesi/Fen Edebiyat Fakültesi/Biyoloji Bölümü.; Bursa Uludağ Üniversitesi/Sağlık Bilimleri Enstitüsü.; 0000-0002-8410-1786; 0000-0002-6729-7908; A-5608-2019; JQI-3400-2023; IWM-5784-2023; HOF-9934-2023; AAG-7012-2021Breast cancer is the most common cancer in women worldwide. MicroRNAs (miRNAs) are non-coding RNAs that are involved in the post-transcriptional regulation of gene expression. Although miRNAs mainly act in the cytoplasm, they can be found in the mitochondrial compartment of the cell. These miRNAs called "MitomiR", they can change mitochondrial functions by regulating proteins at the mitochondrial level and cause cancer.In this review, we have aimed to explain miRNA biogenesis, transport pathways to mitochondria, and summarize mitomiRs that have been shown to play an important role in mitochondrial function, especially in the initiation and progression of breast cancer.Publication A rare cause of central hypothyroidism: Oral isotretinoin treatment(Medcom Ltd, 2019-09-01) Şişman, P.; ÖZ GÜL, ÖZEN; Çalapkulu, Murat; CANDER, SONER; Cander, Soner; Ersoy, Canan; ERSOY, CANAN; Ertürk, Elif; ERTÜRK, ELİF; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0002-7445-2275; AAI-1005-2021; JQI-3400-2023; ABF-6267-2020Publication Cytotoxic potential of rare plant salvia candidissima subsp candidissima on breast cancer cells(Inst Tecnologia Parana, 2023-01-01) Özel, Mustafa Zafer; Fırat, Mehmet; Ertürk, Elif; ERTÜRK, ELİF; Onur, Ömer Enes; Aydın, İpek; İPEK, AYDIN; Arı, Ferda; ARI, FERDA; Bursa Uludağ Üniversitesi/Fen Edebiyat Fakültesi/Biyoloji Bölümü.; 0000-0001-8707-5918; 0000-0002-6729-7908; IUO-8513-2023; AAG-7012-2021; JQI-3400-2023Breast cancer is the leading cause of cancer-related deaths in women throughout the world. Research on natural anti-cancer products from plants has gained traction. Salvia L. species and their derivatives are rare in Turkey and have suggested for their potential anti-cancer effects. The aim of this study is to assess the potential cytotoxic/apoptotic activities of methanol extract of Salvia candidissima Vahl. subsp. candidissima (SCE) on MCF-7 and MDA-MB-231 breast cancer cells. A GCxGC-TOF/MS system and a dual stage commercial thermal desorption injector were used to determine the chemical components of SCE. MTT and ATP viability tests were used to investigate the anti-growth activity. The apoptosis-inducing effect was assessed using a fluorescence staining method. Caspase-cleaved keratin 18 (ccK18, M30-antigen) levels measured by M30-CytoDeath ELISA Kit. The results showed that SCE suppressed the survival of the MCF-7 and MDA-MB-231 breast cancer cells in a dose-dependent manner, based on the findings of both MTT and ATP cell viability tests and pyknotic cell nuclei were observed via fluorescent staining in both cell lines after 48 h of treatment. The treatment group had greater levels of caspase-cleaved keratin 18 in the MCF-7 cells than the untreated group. These results showed that SCE triggers apoptosis, causes cell death in MCF-7 and MDA-MB-231 cell lines. SCE may become promising therapeutic strategy in the treatment of breast cancer with further in vitro and in vivo studies.Publication Investigation of anti-cancer activity of newly synthesized 2,4-pentadien-1-one derivative containing benzofuran in human lung and colon cancer cells(Kare Publ, 2023-01-01) Coşkun, Demet; Arı, Ferda; ARI, FERDA; Tuna, Gonca; Ertürk, Elif; ERTÜRK, ELİF; Bursa Uludağ Üniversitesi/Fen Edebiyat Fakültesi/Biyoloji Bölümü.; 0000-0001-7141-6909; 0000-0002-6729-7908; AAG-7012-2021; IWM-5784-2023Objectives: A member of the flavonoid family, chalcones are natural compounds known to have anticancer effects. Chalcones and their synthetic derivatives have become an important field of interest for cancer research. In this study, we aimed to investigate the anticancer activity of a new Chalcone derivative compound [(2E,4E)-1-(7-ethoxy-1-benzofuran-2-yl)-5-(4-hydroxy-3-methoxyphenyl)penta-2,4-dien-1-one] synthesized by the Claisen-Schmidt reaction based on the curcumin structure in human lung (A549, H1299) and colon cancer (HCT116, HT29) cells. Methods: The effect of Chalcone compound on cell viability was evaluated with the SRB test. In addition, combination studies with 5-FU, which is used as a chemotherapy drug, was performed. The cell death mode was determined by fluorescence imaging method with Hoechst 33342, Annexin-V-FITC and Propidium iodide (PI) triple staining. Results: IC50 values of the Chalcone compound were found as 2.85, 1.46, 0.59, 0.35 mu M for A549, H1299, HCT116, HT29, respectively. As a result of fluorescence imaging, pycnotic nuclei and chromatin condensation were observed in the cells in addition to positive staining with Annexin-V-FITC (green). Conclusion: The results showed that the newly synthesized Chalcone derivative compound has a significant cytotoxic effect on cancer cells and induce apoptosis.Publication Targeting the epithelial-mesenchymal transition (emt) pathway with combination of wnt inhibitor and chalcone complexes in lung cancer cells(Wiley, 2023-07-14) Coşkun, Demet; Arı, Ferda; ARI, FERDA; Ertürk, Elif; ERTÜRK, ELİF; Onur, Ömer E.; Akgün, Oğuzhan; Aydın, İpek; İPEK, AYDIN; Bursa Uludağ Üniversitesi/Fen Edebiyat Fakültesi/Biyoloji Bölümü.; Bursa Uludağ Üniversitesi/Tıbbi Labaratuvar Teknikleri .; 0000-0002-8410-1786; 0000-0002-6729-7908; A-5608-2019; JQI-3400-2023; AAG-7012-2021; IUO-8513-2023Non-small cell lung cancer (NSCLC) is the most common type of the lung cancer. Despite development in treatment options in NSCLC, the overall survival ratios is still poor due to epithelial and mesenchymal transition (EMT) feature and associated metastasis event. Thereby there is a need to develop strategy to increase antitumor response against the NSCLC cells by targeting EMT pathway with combination drugs. Niclosamide and chalcone complexes are both affect cancer cell signaling pathways and therefore inhibit the EMT pathway. In this study, it was aimed to increase antitumor response and suppress EMT pathway in NSCLC cells by combining niclosamide and chalcone complexes. SRB cell viability assay was performed to investigate the anticancer activity of drugs. The drugs were tested on both NSCLC cells (A549 and H1299) and normal lung bronchial cells (BEAS-2B). Then the two drugs were combined and their effects on cancer cells were evaluated. Fluorescence imaging and enzyme-linked immunosorbent assay were performed on treated cells to observe the cell death manner. Wound healing assay, real-time quantitative polymerase chain reaction, and western blot analysis were performed to measure EMT pathway activity. Our results showed that niclosamide and chalcone complexes combination kill cancer cells more than normal lung bronchial cells. Compared to single drug administration, the combination of both drugs killed NSCLC cells more effectively by increasing apoptotic activity. In addition, the combination of niclosamide and chalcone complexes decreased multidrug resistance and EMT activity by lowering their gene expressions and protein levels. These results showed that niclosamide and chalcone complexes combination could be a new drug combination for the treatment of NSCLC.